An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Metabolon Receives NIH Grant to Develop Advanced Monitoring and Predictive Tools for Type 1 Diabetes Progression Morrisville, N.C.- based Metabolon, Inc., has received a grant from the National Institutes of Health (NIH) to develop an innovative product aimed at better monitoring...
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Veracyte Announces that New Afirma GRID Data Suggest Prognostic Ability of Molecular Testing for Thyroid Tumors Veracyte, Inc., announced new research findings suggesting the potential of novel molecular signatures to identify patients with thyroid nodules or cancer who have aggressive disease....
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Xerix Announces Results of Once-Weekly Subcutaneous Hypothyroidism Therapy On May 30, Xeris Biopharma Holdings, Inc., announced topline results from its recently completed Phase 2 multi-center, open label, study of XP-8121 for the treatment of adults with hypothyroidism. XP-8121 employs the Company’s...
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Clinical Trial Interim Data Show Improvements in Pancreatic Function and Glycemic Control with AMX0035 in People with Wolfram Syndrome On April 11, Amylyx Pharmaceuticals announced interim data from the ongoing Phase 2 HELIOS clinical trial of AMX0035 (sodium phenylbutyrate [PB] and...
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Confo Therapeutics Secures Multi-Million Euro Grant On March 28, Belgium-based Confo Therapeutics announced that it has been awarded a EUR 1.6 million grant from Flanders Innovation & Entrepreneurship (VLAIO). The two-year grant will be used to expand Confo’s ongoing R&D efforts...
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Topline Results Announced for CAH Studies On March 13, Spruce Biosciences announced topline results from its CAHmelia-203 study of tildacerfont in adult classic congenital adrenal hyperplasia (CAH) and its CAHptain-205 study of tildacerfont in pediatric classic CAH. Spruce is investigating tildacerfont,...
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Sandoz Receives FDA Approval for Denosumab Biosimilars On March 5, Sandoz announced that the U.S. Food and Drug Administration (FDA) approved Wyost® (denosumab-bbdz) and Jubbonti® (denosumab-bbdz), the first and only FDA-approved denosumab biosimilars, to treat all indications of the reference medicines. Keren Haruvi,...
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Exact Sciences Launches Riskguard™ Hereditary Cancer Test in the U.S. On February 27, Exact Sciences Corp., announced the launch of the Riskguard™ hereditary cancer test in the United States. The Riskguard test provides an individualized patient report that includes gene specific...
